FCM
UTHR icon

Frontier Capital Management’s United Therapeutics UTHR Stock Holding History

Frontier Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150M Buy
252,702
+71,525
+39% +$35.6M 1.54% 3
2025
Q4 		$88.3M Buy
181,177
+7,229
+4% +$3.37M 0.94% 18
2025
Q3 		$72.9M Sell
173,948
-24,635
-12% -$8.28M 0.65% 34
2025
Q2 		$57.1M Sell
198,583
-115,235
-37% -$34.4M 0.53% 62
2025
Q1 		$96.7M Buy
313,818
+70,137
+29% +$24M 1.06% 10
2024
Q4 		$86M Buy
243,681
+64,527
+36% +$23.7M 0.82% 24
2024
Q3 		$64.2M Buy
179,154
+141,518
+376% +$47.8M 0.6% 46
2024
Q2 		$12M Buy
37,636
+4,598
+14% +$1.22M 0.12% 204
2024
Q1 		$7.59M Sell
33,038
-766
-2% -$173K 0.07% 229
2023
Q4 		$7.43M Buy
33,804
+40
+0.1% +$9.22K 0.08% 216
2023
Q3 		$7.63M Sell
33,764
-1,547
-4% -$356K 0.08% 205
2023
Q2 		$7.79M Sell
35,311
-26,021
-42% -$5.76M 0.07% 215
2023
Q1 		$13.7M Sell
61,332
-165,455
-73% -$40.8M 0.14% 172
2022
Q4 		$63.1M Buy
226,787
+39,657
+21% +$10M 0.69% 45
2022
Q3 		$39.2M Sell
187,130
-25,551
-12% -$5.71M 0.46% 67
2022
Q2 		$50.1M Buy
212,681
+33,203
+18% +$6.75M 0.58% 51
2022
Q1 		$32.2M Sell
179,478
-16,910
-9% -$3.22M 0.29% 121
2021
Q4 		$42.4M Buy
196,388
+108,924
+125% +$21.4M 0.34% 107
2021
Q3 		$16.1M Sell
87,464
-22,611
-21% -$4.45M 0.13% 187
2021
Q2 		$19.7M Sell
110,075
-18,630
-14% -$3.55M 0.14% 186
2021
Q1 		$21.5M Buy
128,705
+99,579
+342% +$16.6M 0.16% 165
2020
Q4 		$4.42M Sell
29,126
-3,644
-11% -$478K 0.03% 266
2020
Q3 		$3.31M Sell
32,770
-13,023
-28% -$1.43M 0.03% 273
2020
Q2 		$5.54M Buy
45,793
+6,176
+16% +$695K 0.05% 253
2020
Q1 		$3.76M Buy
+39,617
New +$3.77M 0.04% 249
2017
Q1 		– Sell
-139,264
Closed -$20M – 329
2016
Q4 		$20M Buy
139,264
+76,360
+121% +$9.75M 0.15% 190
2016
Q3 		$7.43M Sell
62,904
-6,014
-9% -$723K 0.06% 255
2016
Q2 		$7.3M Buy
68,918
+30,494
+79% +$3.4M 0.06% 255
2016
Q1 		$4.28M Sell
38,424
-9,807
-20% -$1.24M 0.03% 275
2015
Q4 		$7.55M Buy
48,231
+23,508
+95% +$3.42M 0.06% 266
2015
Q3 		$3.25M Sell
24,723
-95,371
-79% -$15.3M 0.03% 291
2015
Q2 		$20.9M Sell
120,094
-87,734
-42% -$15.8M 0.15% 204
2015
Q1 		$35.8M Buy
207,828
+34,736
+20% +$5.3M 0.26% 150
2014
Q4 		$22.4M Buy
173,092
+48,662
+39% +$6.27M 0.16% 191
2014
Q3 		$16M Sell
124,430
-112,938
-48% -$11.6M 0.13% 218
2014
Q2 		$21M Sell
237,368
-193,666
-45% -$18.6M 0.15% 194
2014
Q1 		$40.5M Buy
431,034
+192,782
+81% +$19.7M 0.29% 126
2013
Q4 		$26.9M Sell
238,252
-551,365
-70% -$49.7M 0.2% 168
2013
Q3 		$62.3M Sell
789,617
-4,640
-0.6% -$339K 0.48% 66
2013
Q2 		$52.3M Buy
+794,257
New +$51.2M 0.43% 78

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Frontier Capital Management's UTHR Position: Q1 2026 in Review

Frontier Capital Management increased its United Therapeutics (UTHR) stake by 39% in Q1 2026, buying an estimated $35.6M and bringing the position to 252,702 shares worth $150M. The position accounts for 1.54% of the portfolio, ranked #3.

Frontier Capital Management first reported a position in UTHR in Q2 2013 and has held it in 40 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Frontier Capital Management held 252,702 shares of United Therapeutics worth $150M as of Q1 2026.
  • Frontier Capital Management bought 71,525 United Therapeutics shares in Q1 2026, an estimated $35.6M.
  • United Therapeutics made up 1.54% of Frontier Capital Management's portfolio in Q1 2026, its #3 holding.
  • Frontier Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Frontier Capital Management's 13F filing for Q1 2026, filed 15 May 2026.